|GRANTWAY
EN

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
07 December 2024
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
United States of America
Health, Justice and Social Welfare
Overview

The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023